Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
R. Servín-Blanco, R. Zamora-Alvarado, G. Gevorkian & K. Manoutcharian. (2016) Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Human Vaccines & Immunotherapeutics 12:10, pages 2640-2648.
Read now
Read now
James L. Gulley, Peter Mulders, Peter Albers, Jacques Banchereau, Michel Bolla, Klaus Pantel & Thomas Powles. (2016) Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm . OncoImmunology 5:4.
Read now
Read now
Geraldine O’Sullivan Coyne & James L Gulley. (2014) Adding fuel to the fire: Immunogenic intensification. Human Vaccines & Immunotherapeutics 10:11, pages 3306-3312.
Read now
Read now
Baijun Dong, Laurie J Minze, Wei Xue & Wenhao Chen. (2014) Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Expert Review of Clinical Immunology 10:11, pages 1547-1557.
Read now
Read now
Articles from other publishers (35)
Lars M. Howell & Neil S. Forbes. (2022) Bacteria-based immune therapies for cancer treatment. Seminars in Cancer Biology 86, pages 1163-1178.
Crossref
Crossref
Ziqi Ye, Shiyu Zheng, Jie Chen, Yanfang Zhang, Si Yang, Yun Hong, Hongyu Yang, Zixue Xuan & Qingwei Zhao. (2022) Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?. International Immunopharmacology 108, pages 108738.
Crossref
Crossref
Xuqing Zhang, Mengyao Luo, Shamael R. Dastagir, Mellissa Nixon, Annie Khamhoung, Andrea Schmidt, Albert Lee, Naren Subbiah, Douglas C. McLaughlin, Christopher L. Moore, Mary Gribble, Nicholas Bayhi, Viral Amin, Ryan Pepi, Sneha Pawar, Timothy J. Lyford, Vikram Soman, Jennifer Mellen, Christopher L. Carpenter, Laurence A. Turka, Thomas J. Wickham & Tiffany F. Chen. (2021) Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. Nature Communications 12:1.
Crossref
Crossref
Mikiya Ishihara, Shinichi Kageyama, Yoshihiro Miyahara, Takeshi Ishikawa, Shugo Ueda, Norihito Soga, Hiroaki Naota, Katsumi Mukai, Naozumi Harada, Hiroaki Ikeda & Hiroshi Shiku. (2020) MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC Cancer 20:1.
Crossref
Crossref
Fumin Hu, Hua Yue, Ting Lu & Guanghui Ma. (2020) Cytosolic delivery of HBsAg and enhanced cellular immunity by pH-responsive liposome. Journal of Controlled Release 324, pages 460-470.
Crossref
Crossref
Ravi A Madan, Emmanuel S Antonarakis, Charles G Drake, Lawrence Fong, Evan Y Yu, Douglas G McNeel, Daniel W Lin, Nancy N Chang, Nadeem A Sheikh & James L Gulley. (2020) Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. JNCI: Journal of the National Cancer Institute 112:6, pages 562-573.
Crossref
Crossref
Sayeh Ezzikouri, Mohammad Enamul Hoque Kayesh, Soumaya Benjelloun, Michinori Kohara & Kyoko Tsukiyama-Kohara. (2020) Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines 8:2, pages 216.
Crossref
Crossref
Eriko Fukuda, Masatoshi Mori, Hiroshi Shiku, Yoshihiro Miyahara, Yoshifumi Kawamura, Koji Ogawa, Toshihiko Ogura & Naoki Goshima. (2019) Development of INSOL‐tag for proteome‐wide protein handling and its application in protein array analysis. Genes to Cells 25:1, pages 41-53.
Crossref
Crossref
Robert L. Coleman, Jinsong Liu, Koji Matsuo, Premal H. Thaker, Shannon N. Westin & Anil K. Sood. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1525
1543.e7
.
Mona Sadat Larijani, Seyed Mehdi Sadat, Azam Bolhassani & Amitis Ramezani. (2019) A Shot at Dendritic Cell-Based Vaccine Strategy against HIV-1. Journal of Medical Microbiology and Infectious Diseases 7:4, pages 89-92.
Crossref
Crossref
Mona Sadat Larijani, Amitis Ramezani & Seyed Mehdi Sadat. (2019) Updated Studies on the Development of HIV Therapeutic Vaccine. Current HIV Research 17:2, pages 75-84.
Crossref
Crossref
Sharon Nyari, Rosemary Booth, Bonnie L. Quigley, Courtney A. Waugh & Peter Timms. (2019) Therapeutic effect of a Chlamydia pecorum recombinant major outer membrane protein vaccine on ocular disease in koalas (Phascolarctos cinereus). PLOS ONE 14:1, pages e0210245.
Crossref
Crossref
Mahsa Keshavarz-Fathi & Nima Rezaei. 2019. Vaccines for Cancer Immunotherapy. Vaccines for Cancer Immunotherapy
153
160
.
Emmanuel S. Antonarakis, Eric J. Small, Daniel P. Petrylak, David I. Quinn, Adam S. Kibel, Nancy N. Chang, Erica Dearstyne, Matt Harmon, Dwayne Campogan, Heather Haynes, Tuyen Vu, Nadeem A. Sheikh & Charles G. Drake. (2018) Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research 24:19, pages 4662-4671.
Crossref
Crossref
Caroline Boudousquie, Giovanna Bossi, Jacob M. Hurst, Karolina A. Rygiel, Bent K. Jakobsen & Namir J. Hassan. (2017)
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
+
and CD4
+
T cells
. Immunology 152:3, pages 425-438.
Crossref
Crossref
James L. Gulley, Ravi A. Madan, Russell Pachynski, Peter Mulders, Nadeem A. Sheikh, James Trager & Charles G. Drake. (2017) Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. JNCI: Journal of the National Cancer Institute 109:4.
Crossref
Crossref
Christopher R. Heery, Ravi A. Madan, Mark N. Stein, Walter M. Stadler, Robert S. Di Paola, Myrna Rauckhorst, Seth M. Steinberg, Jennifer L. Marté, Clara C. Chen, Italia Grenga, Renee N. Donahue, Caroline Jochems, William L. Dahut, Jeffrey Schlom & James L. Gulley. (2016) Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget 7:42, pages 69014-69023.
Crossref
Crossref
G. Coukos, J. Tanyi & L.E. Kandalaft. (2016) Opportunities in immunotherapy of ovarian cancer. Annals of Oncology 27, pages i11-i15.
Crossref
Crossref
Susan F. Slovin. 2016. Prostate Cancer. Prostate Cancer
523
531
.
Zhenlong Ye, Zhong Li, Huajun Jin & Qijun Qian. 2016. Progress in Cancer Immunotherapy. Progress in Cancer Immunotherapy
139
167
.
Susan F. Slovin. 2016. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
107
124
.
Eric J. Small, Raymond S. Lance, Thomas A. Gardner, Lawrence I. Karsh, Lawrence Fong, Candice McCoy, Todd DeVries, Nadeem A. Sheikh, Debraj GuhaThakurta, Nancy Chang, Charles H. Redfern & Neal D. Shore. (2015) A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 21:17, pages 3862-3869.
Crossref
Crossref
Neal D. Shore. (2015) Advances in the understanding of cancer immunotherapy. BJU International 116:3, pages 321-329.
Crossref
Crossref
Debraj GuhaThakurta, Nadeem A. Sheikh, Li-Qun Fan, Harini Kandadi, T. Craig Meagher, Simon J. Hall, Philip W. Kantoff, Celestia S. Higano, Eric J. Small, Thomas A. Gardner, Kate Bailey, Tuyen Vu, Todd DeVries, James B. Whitmore, Mark W. Frohlich, James B. Trager & Charles G. Drake. (2015) Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research 21:16, pages 3619-3630.
Crossref
Crossref
Gregory T. Kennedy, Brendan F. Judy, Pratik Bhojnagarwala, Edmund K. Moon, Zvi G. Fridlender, Steven M. Albelda & Sunil Singhal. (2015) Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma. Immunology Letters 166:1, pages 28-35.
Crossref
Crossref
Christopher R. Heery & James L. Gulley. 2014. Cancer Consult: Expertise for Clinical Practice. Cancer Consult: Expertise for Clinical Practice
826
830
.
B. Harpreet Singh & James L. Gulley. (2014) Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Therapeutic Advances in Vaccines 2:5, pages 137-148.
Crossref
Crossref
James L. Gulley, Ravi A. Madan, Kwong Y. Tsang, Caroline Jochems, Jennifer L. Marté, Benedetto Farsaci, Jo A. Tucker, James W. Hodge, David J. Liewehr, Seth M. Steinberg, Christopher R. Heery & Jeffrey Schlom. (2014) Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunology Research 2:2, pages 133-141.
Crossref
Crossref
Jeffrey Schlom, James W. Hodge, Claudia Palena, Kwong-Yok Tsang, Caroline Jochems, John W. Greiner, Benedetto Farsaci, Ravi A. Madan, Christopher R. Heery & James L. Gulley. 2014.
67
124
.
Caroline Jochems, Jeffrey Schlom & James L. Gulley. 2014. Novel Technologies for Vaccine Development. Novel Technologies for Vaccine Development
291
327
.
Lana E. Kandalaft, Klara Balint, Jonathan S. Berek & George Coukos. 2014. Controversies in the Management of Gynecological Cancers. Controversies in the Management of Gynecological Cancers
323
337
.
Adam Rojan, Renee Funches, Meredith M. Regan, James L. Gulley & Glenn J. Bubley. (2013) Dramatic and Prolonged PSA Response After Retreatment With a PSA Vaccine. Clinical Genitourinary Cancer 11:3, pages 362-364.
Crossref
Crossref
James L. Gulley, Christopher R. Heery, Ravi A. Madan, Beatriz A. Walter, Maria J. Merino, William L. Dahut, Kwong-Yok Tsang, Jeffrey Schlom & Peter A. Pinto. (2013) Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunology, Immunotherapy 62:9, pages 1521-1531.
Crossref
Crossref
Nishith Singh, Ravi Madan & James L Gulley. (2013) Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. Clinical Investigation 3:7, pages 651-663.
Crossref
Crossref
James L. GulleyRavi A. MadanChristopher R. Heery. (2013) Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book:33, pages e166-e170.
Crossref
Crossref